$SYRS

Syros Pharmaceuticals Inc.

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$0.6707 β–Ό-3.566%

Delayed Price

VOLUME

200,233

DAY RANGE

-

52 WEEK

0.65 - 7.03

Join Discuss about SYRS with like-minded investors

See 1 more SYRS posts
profile
@dros #droscrew
recently

Positive Initiations 11/10: $A $ABBV $ALGS $ASAN $BLFS $BLI $BMRA $BRKS $CDMO $CSTL $CYRX $DHR $EAR $HBIO $OCX $PLAN $PRAX $RGEN $SYRS $TARS $VRM $WK $WST $XGN

132 Replies 11 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

Upgrades 11/4: $ADTN $AM $AMD $AMZN $BIDU $FMS $SPR $SYRS $SYY $TER $VC

106 Replies 7 πŸ‘ 6 πŸ”₯

Load more...

Key Metrics

Market Cap

43.69 M

Beta

1.74

Avg. Volume

864.06 K

Shares Outstanding

62.82 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARΞ± agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

CEO: Nancy Simonian

Website:

HQ: 35 Cambridge Park Drive Cambridge, 02140 Massachusetts

Related News